Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

CYTK Cytokinetics Inc.
$69.39 0.12% +0.08
Notify me if price changes either direction
Interactive Brokers Logotype

Buy CYTK stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 9.6B
Enterprise value 10.3B
Trailing PE -10.610091649793
Forward PE -16.274023
PEG Ratio -0.31271849073075
Enterprise to EBITDA -14.857
Enterprise to revenue 152.668
Price to book MRQ -52.830745009027
Price to sales TTM 148.8436

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 67.7M
EBITDA -695361984
Diluted EPS TTM -7.22
Total Cash (MRQ) 1.2B
Current ratio (MRQ) 6.661
Operating Cash Flow (TTM) -555452992

CYTK trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent CYTK News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.